Crinetics Pharmaceuticals has been granted a patent for formulations of a somatostatin modulator, useful in treating conditions benefiting from somatostatin activity modulation. The patent includes a method of suppressing growth hormone, insulin, glucagon, IGF-1, and prolactin in humans through oral administration of a specific pharmaceutical composition. GlobalData’s report on Crinetics Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Crinetics Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Crinetics Pharmaceuticals's grant share as of May 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for oral method to suppress hormones
A recently granted patent (Publication Number: US11957674B2) discloses a method for suppressing growth hormone (GH), insulin, glucagon, insulin-like growth factor 1 (IGF-1), prolactin, or combinations thereof in humans. The method involves orally administering a pharmaceutical composition containing a specific compound, 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile, on an empty stomach at least 30 minutes before a meal. This method is particularly useful for individuals with conditions such as acromegaly or neuroendocrine tumors.
The pharmaceutical composition mentioned in the patent comprises specific ratios of the active compound and other pharmaceutical acceptable ingredients. The composition is designed to be administered once daily with a glass of water on an empty stomach. The patent outlines various formulations of the pharmaceutical composition, including spray dried dispersions with specific polymer matrices and ratios of active ingredients to excipients. The method also specifies the dosage range of the active compound, ranging from about 20 mg to about 60 mg of 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile monohydrochloride. Overall, the patent provides a detailed and specific method for effectively suppressing certain hormones in humans using the disclosed pharmaceutical composition.
To know more about GlobalData’s detailed insights on Crinetics Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
